These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18959599)

  • 41. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives.
    Ahrén B
    Diabetes Metab; 2013 May; 39(3):195-201. PubMed ID: 23643349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Incretin and bone].
    Yamada Y
    Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
    Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minireview: update on incretin biology: focus on glucagon-like peptide-1.
    Brubaker PL
    Endocrinology; 2010 May; 151(5):1984-9. PubMed ID: 20305008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on incretin hormones.
    Phillips LK; Prins JB
    Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide.
    Widenmaier SB; Sampaio AV; Underhill TM; McIntosh CH
    J Biol Chem; 2009 Apr; 284(16):10764-73. PubMed ID: 19233842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucose-dependent Insulinotropic Polypeptide (GIP) Resistance and β-cell Dysfunction Contribute to Hyperglycaemia in Acromegaly.
    Shekhawat VS; Bhansali S; Dutta P; Mukherjee KK; Vaiphei K; Kochhar R; Sinha SK; Sachdeva N; Kurpad AV; Bhat K; Mudaliar S; Bhansali A
    Sci Rep; 2019 Apr; 9(1):5646. PubMed ID: 30948746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
    Matuszek B; Lenart-Lipińska M; Nowakowski A
    Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    Diabetes Obes Metab; 2017 May; 19(5):744-748. PubMed ID: 28181363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS; Jun HS
    Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
    Gautier JF; Choukem SP; Girard J
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut peptides in the treatment of diabetes mellitus.
    Vahl TP; D'Alessio DA
    Expert Opin Investig Drugs; 2004 Mar; 13(3):177-88. PubMed ID: 15013938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide.
    Khan R; Tomas A; Rutter GA
    Peptides; 2020 Mar; 125():170201. PubMed ID: 31751656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucagon-like peptide-1 and gastric inhibitory polypeptide: new advances.
    Gallwitz B
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):23-7. PubMed ID: 26702848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.